Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
TFPI encodes a protease inhibitor that regulates the tissue factor (TF)-dependent pathway of blood coagulation. Additionally we are shipping TFPI Kits (81) and TFPI Proteins (41) and many more products for this protein.
Showing 10 out of 184 products:
Human Polyclonal TFPI Primary Antibody for ELISA, WB - ABIN256599
Wun, Kretzmer, Girard, Miletich, Broze: Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. in The Journal of biological chemistry 1988
Human Polyclonal TFPI Primary Antibody for IF (p) - ABIN741697
Gustafson, Shepherd, Miller, Jayachandran: Age- and sex-specific differences in blood-borne microvesicles from apparently healthy humans. in Biology of sex differences 2015
Human Polyclonal TFPI Primary Antibody for ELISA, WB - ABIN4369732
Hansen, Petersen, Lauritzen, Clausen, Grell, Agersø, Sørensen, Hilden, Almholt: Target-mediated clearance and bio-distribution of a monoclonal antibody against the Kunitz-type protease inhibitor 2 domain of Tissue Factor Pathway Inhibitor. in Thrombosis research 2014
TFPI-1 interacts with AMOT (show AMOT Antibodies), which led to a decrease in the phosphorylation of YAP (show YAP1 Antibodies) and further increased the genes expression of the proliferation and migration involved. Our results further confirmed that atherosclerosis was a localized disease.
Results suggest that endothelial cell-anchored TFPI controls lung tumor metastasis, and does so largely through the inhibition of local TF-induced thrombin (show F2 Antibodies) generation and the regulation of the lung microenvironment in mice.
Data argue against an important role for endogenous TFPI in the antibacterial, inflammatory and procoagulant response during pneumococcal pneumonia.
TFPI has an anti-proliferative role in TNF-alpha (show TNF Antibodies) stimulated-VSMCs at least partly by interfering with the MCP-3 (show CCL7 Antibodies)/CCR2 (show CCR2 Antibodies) pathway and then via suppression of the ERK1/2 (show MAPK1/3 Antibodies) and PI3K/AKT (show AKT1 Antibodies) signaling pathways
Results demonstrate that TFPI physiologically modulates thrombin (show F2 Antibodies)-dependent platelet activation in a manner that is required for successful embryonic development
Tissue factor (show F3 Antibodies) plays a hitherto unreported role in the generation of macrophage migratory inhibitory factor by vascular smooth muscle cells in atherosclerosis-prone ApoE (show APOE Antibodies)(-/-) mice.
The increased plasmin (show PLG Antibodies) generation during the early stages of sepsis could cleave/inactivate TFPI and thus lead to thrombotic complications.
structural features within residues of the 39-loop contribute to the resistance of FIXa (show ETFB Antibodies) to inhibition by plasma inhibitors ZPI (show SERPINA10 Antibodies) and TFPI.
PAK1 (show PAK1 Antibodies) negatively regulates the expression of TFPI and additionally contributes to increased TF activity.
Murine models of combined TFPI and factor VIII deficiency were used to examine the impact of TFPI deficiency on bleeding and clotting in hemophilia
The aim of this study was to evaluate the concentration of TF and its inhibitor TFPI in blood plasma, the impact of traditional and non-traditional cardiovascular risk factors on their concentration and the impact of both markers of haemostasis on the severity of subclinical atherosclerosis.
The results show that cholesterol crystals induce TFPI and cytokine expression in M2-polarized macrophages through activation of the endoplasmic reticulum stress pathway and that TFPI has a protective effect against TNF-alpha (show TNF Antibodies) and IL-6 (show IL6 Antibodies) mediated inflammation.
Among high-risk women, the tissue factor pathway inhibitor activity of patients with gestational vascular complications is higher than that in other patients. Hence, these markers could augment a screening strategy.
TFPI single nucleotide polymorphism is associated with venous thromboembolism.
a concentration of tissue factor pathway inhibitor was significantly lower in patients with essential thrombocythemia with JAK2 (show JAK2 Antibodies) V617F mutation as compared with patients without the mutation
This review presents a comprehensive understanding of TFPI structure, biochemistry, and cellular expression which is necessary to understand how it modulates bleeding in hemophilia and the physiological impact of therapeutic agents targeting TFPI.
the main finding of the current study is the remarkable elevation in the plasma levels of both total and free TFPI in septic patients at baseline. The levels of both forms of the inhibitor remained elevated throughout the first 24 h with further elevation after enoxaparin administration.
TFPI-1 was a valuable predictor of deep venous thrombosis and tumor metastasis in non-small cell lung cancer patients.
Circulating FVII (show F7 Antibodies), FVIIa and TFPI were significantly elevated in women with severe preeclampsia in the absence of comparable changes in plasma TF levels.
HIF-1alpha (show HIF1A Antibodies) is involved in the transcriptional regulation of the TFPI gene, and suggests that a hypoxic microenvironment inside a breast tumor may induce a procoagulant state in breast cancer patients.
Upregulated TF expression and increased plasma TF level during reperfusion period, reduced plasma TFPI-1 level during reperfusion period.
This gene encodes a protease inhibitor that regulates the tissue factor (TF)-dependent pathway of blood coagulation. The coagulation process initiates with the formation of a factor VIIa-TF complex, which proteolytically activates additional proteases (factors IX and X) and ultimately leads to the formation of a fibrin clot. The product of this gene inhibits the activated factor X and VIIa-TF proteases in an autoregulatory loop. The encoded protein is glycosylated and predominantly found in the vascular endothelium and plasma in both free forms and complexed with plasma lipoproteins. Several alternatively spliced transcript variants of this gene have been described, but the full-length nature of some of these variants has not been confirmed.
extrinsic pathway inhibitor
, lipoprotein-associated coagulation inhibitor
, uncharacterized protein LOC100155068
, tissue factor pathway inhibitor